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Many biological functions follow circadian rhythms driven by
internal and external cues that synchronize and coordinate
organ physiology to diurnal changes in the environment
and behavior. Urinary acid–base parameters follow diurnal
patterns and it is thought these changes are due to periodic
surges in gastric acid secretion. Abnormal urine pH is a risk
factor for specific types of nephrolithiasis and uric acid stones
result from excessively low urine pH. Here we placed
9 healthy volunteers and 10 uric acid stone formers on
fixed metabolic diets to study the diurnal pattern of urinary
acidification. All showed clear diurnal trends in urinary
acidification, but none of the patterns were affected by
inhibitors of the gastric proton pump. Uric acid stone formers
had similar patterns of change throughout the day but their
urine pH was always lower compared to healthy volunteers.
Uric acid stone formers excreted more acid (normalized
to acid ingestion), with the excess excreted primarily as
titratable acid rather than ammonium. Urine base excretion
was also lower in uric acid stone formers (normalized to
base ingestion), along with lower plasma bicarbonate
concentrations during part of the day. Thus, increased net
acid presentation to the kidney and the preferential use
of buffers, other than ammonium, result in much higher
concentrations of undissociated uric acid throughout the
day and consequently an increased risk of uric acid stones.
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A property intrinsic to living organisms is the biological
circadian clock, which is organized and oscillates at multiple
hierarchies at both cellular1,2 and multicellular levels3,4
in both the animal and plant kingdoms.5,6 In mammalian
biology, many aspects of behavior and physiology follow
cyclic rhythms, which are generally presumed to confer
adaptive advantage by coordinating behavior and organ
physiology to ambient day-and-night cycles.4 In the kidney,
significant circadian rhythms exist for multiple renal
hemodynamic, glomerular, and tubular parameters.7,8 These
renal circadian rhythms are influenced by external cues such
as feeding, ambient light, and activity, as well as inherently by
intrinsic clocks.9,10
In 1845, Henry Bence Jones, who is considered to be the
pioneer of urinary chemistry for his studies of urinary light
chains, glucose, and cystine in disease states,11 noted diurnal
variation in urine pH (UpH) in normal individuals.12
Subsequent studies also demonstrated morning alkaline and
evening acidic trends of urine although this finding was not
always uniformly observed.13–18 However, the precise circa-
dian profile of urine acidification remains incompletely
defined, and the factors responsible for hour-to-hour
fluctuations in pH are not known. Gastric acid secretion
with the concomitant alkalization of plasma has been
proposed to be the origin of postprandial changes in plasma
pH and UpH.19,20 In addition, it is unclear whether renal
disorders affect circadian patterns of urinary chemistry and
whether such derangements in rhythmic changes in urinary
acidification contribute to pathophysiology.
Although the kidney is capable of elaborating urine at
an enormously wide range of hydrogen ion concentrations
when stressed (pH from o5 to 48; [Hþ ] from o10 nM to
410 mM), normal day-to-day UpH is poised within a much
narrower span in humans somewhere between pH 5.5
and 6.5. Acidification of urine is of critical importance
for prevention of calcium phosphate crystallization in the
urinary space.21–23 However, UpH cannot be lowered too
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much because of another constraint in higher primates who
maintain relatively high plasma and urinary uric acid.22,24
Urinary acidification to below pH 5.5, although protective
against calcium phosphate precipitation, poses a substantial
risk of uric acid precipitation.22 Precipitation of calcium
phosphate and uric acid thus set the upper and lower limits
of UpH, respectively, and calcium phosphate and uric acid
nephrolithiasis in fact represent quintessential clinical
disorders of UpH.
In humans with uric acid nephrolithiasis, excessively
acidic urine causes titration of urate to the highly insoluble
uric acid despite normal or even low total uric acid content
in urine. The pathogenesis of low UpH has been ascribed
to both increased acid load to the kidney and defective
utilization of ammonia in urinary buffering.25–31 It is not
clear whether the unduly acidic urine in uric acid stone
formers (UASFs) occurs at specific intervals or persists
throughout the day. Current standard clinical practice,
clinical investigations, and clinical trials, all use 24-h urine
collections to assess risk for uric acid stones and adequacy of
response to therapy. We reported that during treatment of
uric acid nephrolithiasis with alkali, excessive nocturnal and
early-morning urinary acidity can linger despite apparent
alkalinization of pooled 24-h urine.32 This can potentially
result in a false sense of security for the clinician that uric
acid stone risk is eliminated, but an elevated propensity for
uric acid precipitation still persists in the patient during
specific periods of the day. Although most patients likely
respond to daytime alkali therapy, the possibility remains in
some individuals where persistent early-morning aciduria
can sustain the elevated stone risk despite alkali therapy.
The study of 24-h urine profiles in UASFs will enhance our
understanding of its pathophysiology and the origin of the
excessive aciduria. It will also guide us in designing better
clinical tests for diagnosis and monitoring of therapy in
uric acid nephrolithiasis. We embarked to detail the circadian
pattern of urinary acidification parameters in normal
volunteers to delineate normal circadian physiology and in
UASFs to identify pathophysiological defects. In addition, we
tested the longstanding belief that gastric acid secretion
contributes to changes in UpH by blocking gastric acid
production in the two groups of subjects.
RESULTS
Demographic characteristics
The demographic characteristics of the study population are
depicted in Table 1. Ten UASFs and nine healthy volunteers
(HVs) participated in the study. Most of the subjects in both
groups were male and non-Hispanic Caucasians, which is
typical of UASFs. The mean age did not differ significantly
between the two groups. The UASFs weighed more and had a
higher BMI than the HVs.
Serum and urine chemistry
Table 2 shows the fasting serum chemistry for both groups in
each study phase. In both phases, UASFs had a slightly higher
serum creatinine level due to higher creatinine production
rate, but creatinine production rate per body mass was
not different between the two groups. Most importantly,
creatinine clearance was not different between the two
groups. Serum uric acid was persistently higher in UASFs
in both phases of the study. Serum bicarbonate, chloride, and
venous pH did not differ between the two groups. UASFs
taking placebo demonstrated a very slight but statistically
significantly higher serum potassium level than in the proton
pump inhibitor (PPI) phase and higher than HVs in both
phases.
Urine was collected for 24 h prior to each diurnal study
and results are shown in Table 3. In both study phases, UpH
in UASFs was significantly lower than in HVs (UASFs vs. HVs
in placebo phase: 5.42±0.36 vs. 5.86±0.28; P¼ 0.01; UASFs
vs. HVs in PPI phase: 5.32±0.36 vs. 5.93±0.23; Po0.001).
Urinary sodium, potassium, sulfate, and phosphate did not
differ among the groups, indicating equivalence of dietary
intake. In both phases, citrate excretion was numerically
lower in UASFs but the difference was not statistically
Table 1 | Patient demographic data
Healthy volunteers
(HVs)
Uric acid stone
formers (UASFs)
Gender: M/F 6/3 9/1
Race (white/black) 7/2 9/1
Ethnicity
(non-Hispanic/Hispanic)
9/0 9/1
Age (years) 52.8±13.1 57.0±8.2
Weight (kg) 85±19 109±19*
Height (cm) 171±10 172±6
Body mass index (kg/m2) 28.5±4.3 36.9±6.8*
Abbreviations: F, female; M, male.
*Po0.05, t-test.
Table 2 | Fasting serum profile
Placebo PPI
HV UASF HV UASF
Creatinine (mg/dl)
(mmol/l)
0.84±0.13
74±11
1.06±0.02*
94±1.7
0.88±0.15
78±13
1.12±0.21w
99±18
Creatinine clearance
(ml/min)
(ml/min per 1.73m2)
139±35
120±20
131±39
100±26
129±35
112±17
126±36
95±23
Glucose (mg/dl)
(mmol/l)
97±10
5.4±0.6
103±25
5.6±1.4
96±6
5.3±0.3
106±26
5.0±1.4
Uric acid (mg/dl)
(mmol/l)
6.0±1.6
357±95
8.0±1.5*
476±89
6.3±1.6
375±95
8.1±1.5w
482±89
Sodium (mEq/l) 139±3 138±3 138±2 138±2
Potassium (mEq/l) 4.0±0.3 4.5±0.7* 3.9±0.2 4.0±0.3z
Chloride (mEq/l) 106±3 107±2 107±2 107±3
Bicarbonate (mEq/l) 27.0±1.3 26.1±3.3 26.7±1.5 25.9±1.1
Venous pH 7.41±0.02 7.40±0.02 7.41±0.01 7.40±0.01
Abbreviations: HV, healthy volunteer; PPI, proton pump inhibitor; UASF, uric acid
stone former.
*Po0.05 UASF vs. HV; on placebo.
wPo0.05 UASF vs. HV; on PPI.
zPo0.05 UASF placebo vs. UASF on PPI.
Comparisons made with mixed-model repeated-measures analysis.
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significant. Twenty-four-hour titratable acidity (TA) and net
acid excretion (NAE) was higher, and urinary ammonium
was lower numerically in UASFs compared to HVs, although
none of the differences reached a P value of o0.05 in this
small cohort. However, the proportion of NAE as ammo-
nium (NH4/NAE) was significantly lower in UASFs (UASFs
vs. HVs in placebo phase: 0.55±0.08 vs. 0.75±0.07;
P¼ 0.003; UASFs vs. HVs in PPI phase: 0.55±0.15 vs.
0.78±0.16, P¼ 0.001). Twenty-four-hour urinary uric acid
excretion did not differ between the groups. There was no
difference between the placebo and PPI phase.
Diurnal study
Figure 1a and b depicts the diurnal UpH in the HVand UASF
group under each study phase. Throughout the day, both
HVs and UASFs demonstrated marked variations in UpH. In
both groups, UpH increased in the morning, peaked at
noon, fell following lunch, rose again during the afternoon,
and fell again after the evening meal. A nocturnal peak in
UpH was usually seen around 2200 hours. Throughout the
night, UpH decreased to a nadir around 0600 hours before
rising again in the morning. Changes in UpH over time
are statistically significant within HV and UASF groups in
either the placebo or the PPI phases (HV-placebo, HV-PPI,
UASF-placebo, UASF-PPI, all Po0.001). The shape of the
curves did not differ between the placebo and PPI phases for
both HVs and UASFs (P¼ 0.95). PPI treatment had no effect
on the value or profile of UpH (P¼ 0.60 for HVs; P¼ 0.72
for UASFs).
Throughout the day, UpH was significantly lower in
UASFs than in HVs in either the placebo (Figure 1c) or the
PPI phase (similar to placebo; not shown) (Po0.001).
However, the time profile of UpH was not statistically
different between the two groups (HVs vs. UASFs; P¼ 0.14)
in placebo phase. In contrast to HVs on PPI, the UASFs
receiving PPI demonstrated a slightly blunted curve in the
evening and overnight (P¼ 0.05).
Table 3 | Baseline 24-h urine chemistry
Placebo PPI
HV UASF HV UASF
Total volume (l/day) 2.77±0.91 2.07±0.67 2.69±1.02 2.33±0.86
pH 5.86±0.28 5.42±0.36* 5.93±0.23 5.32±0.36w
Creatinine (g/day)
(mmol/day)
1.7±0.6
15.0±5.3
1.9±0.5*
18.8±4.4
1.6±0.5
14.2±4.4
2.0±0.5
17.7±0.5
Potassium (mEq/day) 43±13 45±12 45±14 42±13
Sulfate (mEq/day) 41.2±9.6 41.0±9.0 39.6±10 37.4±12
Phosphate (mg/dl)
(mM)
704±291
22.7±9.4
807±304
26.0±9.8
683±307
22.0±9.9
789±220
22.5±7.1
Ammonium (NH4)
(mEq/day)
39±15 32±16 39±19 33±12
Titratable acid (mEq/day) 24±9 33±9z 25±11 34±9**
Citrate (mEq/day) 9.9±3.7 7.3±4.88 9.1±2.2 6.2±3.8w
Bicarbonate (mEq/day)
Median (range)
1.1±2.1
0 (0–5.6)
0.3±0.9
0 (0–2.72)
1.6±2.1
0 (0–5.9)
0.4±1.1w
0 (0–3.3)
Uric acid (mg/day) 657±337 540±322 570±123 472±273
Net acid excretion (NAE)
(mEq/day)
53±20 58±22 53±29 60±12
NAE/sulfate (mEq/mEq) 0.75±0.07 0.55±0.08* 0.78±0.16 0.55±0.15w
NH4/NAE 0.75±0.07 0.55±0.08* 0.78±0.16 0.55±0.15
w
Urinary unmeasured
anions (mEq/day)
4.5±12.9 10.3±8.7 7.8±9.9 6.9±11.1
Fractional excretion
of uric acid (%)
5.9±2.6 4.0±2.6* 5.4±2.1 3.5±2.0w
Abbreviations: HV, healthy volunteer; PPI, proton pump inhibitor; UASF, uric acid
stone former.
*Po0.05 UASF vs. HV; placebo.
wPo0.05 UASF vs. HV; on PPI.
zP=0.08 UASF vs. HV; placebo.
**P=0.06 UASF vs. HV; on PPI.
8P=0.07 UASF vs. HV; placebo.
Comparisons made with mixed-model repeated-measures analysis.
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Figure 1 |Urine pH (UpH) in uric acid stone formers (UASF)
and healthy volunteers (HV). (a) Placebo vs. protein pump
inhibitors (PPI) in HV. (b) Placebo vs. PPI in UASF. (c) HV vs. UASF.
Meals are indicated by black boxes.
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Figure 2 compares urinary excretion rates of principal
acid–base components in HVs and UASFs during the
placebo phase. As there was no difference between PPI and
placebo, only the placebo phase is shown. In both HVs and
UASFs, excretion of these solutes varied significantly over
time (all Po0.001). Acid excretion in general is higher in
the late afternoon and evening, likely reflecting the fact
that the protein for breakfast is less than that for lunch and
dinner (protein: breakfast 7 g, lunch 24 g, dinner 30 g).
Urinary ammonium excretion rate (Figure 2a) did not differ
between HVs and UASFs in regard to both amount (P¼ 0.11)
and pattern (P¼ 0.40). The pattern of TA excretion also
did not differ between the groups (P¼ 0.27). However, the
amount of TA was significantly higher in the UASF group
(P¼ 0.005) (Figure 2b). The amount and pattern of the
two urinary bases differed between the groups. USAFs
excreted less bicarbonate (P¼ 0.01) and had a flatter bicar-
bonate profile (P¼ 0.05) compared with HVs (Figure 2c). In
addition, UASFs excreted significantly less citrate (P¼ 0.012)
and tended to have a different citrate pattern (P¼ 0.056),
with blunted citrate excretion in the UASFs occurring mostly
in the morning.
Plasma bicarbonate concentration changed significantly
during the 24-h period (Po0.001 for both groups), but the
pattern was similar in HVs and UASFs (P¼ 0.94) (Figure 3a).
However, serum bicarbonate was higher in HVs compared
with UASFs throughout the day (P¼ 0.003). There were no
differences between the PPI and placebo phase in either
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Figure 2 | Excretion of acid–base parameters in healthy volunteers (HV) and uric acid stone formers (UASF). (a) Ammonium.
(b) Bicarbonate. (c) Titratable acid. (d) Citrate. Black boxes represent meals.
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Figure 3 |Plasma acid–base parameters in uric acid stone
formers (UASF) and healthy volunteers (HV). (a) Bicarbonate.
(b) pH. Black boxes represent meals.
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healthy volunteers or UASFs for both pH and bicarbonate, so
only the placebo data are shown in Figure 3. Interestingly,
despite the differences in bicarbonate concentrations, changes
in venous pH over time did not reach statistical significance
within either group during the two treatment periods
(P¼ 0.21) and did not differ between the groups (P¼ 0.45)
(Figure 3b).
UASFs have higher NAE than HVs even though they are
on identical metabolic diets (Figure 4a). The equivalence
of dietary acid load is proven by the same amount and
pattern of sulfate excretion (Figure 4b). Although exo-
genous dietary acid load was equivalent, UASFs have
consistently higher acid excretion throughout the day, with
the exception of perhaps the period around 1800–2000
hours in the evening. This is best illustrated by the
consistently higher NAE/sulfate ratio throughout the day
in UASFs (Figure 4c) (P¼ 0.02). The higher acid load is
also compatible with the lower citrate excretion (Figure
2d). Potassium excretion can be used as a surrogate for
dietary alkali intake. UASFs have the same potassium
excretion as HVs, but lower citrate excretion per K ingested
(P¼ 0.001) (Figure 4d).
Figure 5 shows the most important determinant of uric
acid stone risk in the UASFs. Absolute rates or patterns of
total uric acid excretion did not differ between the two
groups (P¼ 0.45) and there was no difference in the time
profile in excretion between the two groups (P¼ 0.7) (Figure
5a). However, UASFs had persistently about twice the
undissociated uric acid content in urine as HVs (Figure 5b)
(Po0.001).
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Figure 4 |Urinary acid–base parameters normalized to dietary surrogates of acid (sulfate) or base (potassium) ingestion, in uric acid
stone formers (UASF) and healthy volunteers (HV). (a) Net acid excretion. (b) Sulfate excretion. (c) Net acid per sulfate. (d) Citrate per
potassium. Black boxes represent meals.
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Figure 5 |Uric acid excretion in uric acid stone formers (UASF)
and healthy volunteers (HV). (a) Total (urate + undissociated
uric acid). (b) Undissociated uric acid excretion in urine. Black
boxes represent meals.
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DISCUSSION
Instead of examining pooled 24-h samples, we tried to define
the circadian variation of UpH and acid–base parameters in
healthy subjects as well as in UASFs. We also examined the
contribution of gastric acid secretion to circadian variation in
both groups and evaluated whether differences in gastric acid
secretion are responsible for a lower UpH in UASFs vs. HVs.
Both HVs and UASFs were placed on a strict metabolic
diet, thereby eliminating exogenous factors on acid–base
balance. Both groups demonstrated significant variations in
UpH throughout the day, and these changes were temporally
related to meals. Although there was little change immedi-
ately following breakfast, UpH declined after the noon and
evening meals. UpH subsequently rose and peaked approxi-
mately 4 h after each meal. Overnight UpH fell steadily,
before it began to rise in the early morning hours. While they
confirm the previously described ‘morning alkaline tide’, our
data did not demonstrate a true post-prandial alkaline tide in
either blood or urine. A rise in serum pH after the ingestion
of a meal was described previously,19,20 while there is
conflicting evidence for whether there is a consistent post-
prandial alkaline tide in the urine.33,34 This difference may, in
part, be due to variances in diet, timing of urine collections,35
and use of pH paper to define UpH in some studies.33,34 In
our study, the higher frequency of urine collections allowed
for a higher resolution, and the instant measurement using
a pH electrode permitted more accurate assessment of
circadian changes. The decline in UpH following lunch and
dinner may not have been appreciated previously, because of
longer post-prandial urine collection times.
The post-prandial alkaline tide described in serum raises
expectations that a similar phenomenon might occur in the
urine due to increased filtered bicarbonate load. However,
there are multiple factors that contribute to the UpH. The
increased filtered load of HCO3
 may or may not exceed
tubular reabsorption and the production and excretion of
non-bicarbonate buffers will also affect UpH significantly.
The effects of variations in diet are also unclear. The UpH
may reflect the combined effects of gastric acid and
pancreatic bicarbonate secretion, and the extent of each
process may alter the UpH. Others have shown that patients
after vagotomy, receiving H2-blockers or PPI have varying
degrees of blunted post-prandial alkaline tide in the
blood.19,20,33,34,36 If gastrointestinal acid or base secretion
was responsible for diurnal UpH changes, then administra-
tion of a proton pump inhibitor would completely block
those effects. Our study did not demonstrate any effect of the
PPI medication, thus raising into question the role of gastric
acid secretion in affecting UpH. Alternative mechanisms
that may account for these variations include circadian clock
genes, which have been found to control acid–base transport-
ers in the kidney.37,38 Further investigation of such genes
may help identify the mechanisms responsible for circadian
variation in UpH.
Several features are noteworthy in the UASFs. Despite the
more acidic urine, the circadian pattern is well preserved in
UASFs. Unlike some previous studies reporting lack of
diurnal changes in the UpH of UASFs,39,40 we found that
UASFs exhibited the same peaks and troughs overnight and
in relation to meals, as in HVs. Previous studies were
performed in a smaller number of UASFs, without using
strict metabolic diets, and collected urines in wider (46-h)
intervals. However, at each time point, UASFs’ UpH was
significantly more acidic than that of HVs. With the
exception of two time points, UASFs maintained a mean
UpH of p5.6 throughout all time points of the day, which
significantly contributes to uric acid stone development.24
The undissociated uric acid excretion rate and concentration
are much higher in UASFs throughout the entire 24-h period.
Differences in the diurnal excretion of ammonium, TA,
citrate, and bicarbonate reflect the findings previously
described in pooled 24-h urine collections,30 but a higher
time resolution is presented in this diurnal study. UASFs
demonstrated lower citrate, and bicarbonate excretion and
higher TA, which persisted throughout the entire day. Each
urinary component exhibited a circadian pattern of excre-
tion. The citrate and bicarbonate plots were slightly blunted
in the UASFs, indicating possibly a different pattern of
excretion. Both groups excreted ammonium and TA in a
similar pattern. It has been suggested that increased acid
production in UASFs may account for lower UpH.26,31,41 This
mechanism may also account for consumption of base and
the differences observed in the diurnal excretion of alkali.
In addition to a lower UpH, UASFs demonstrated persis-
tently lower serum bicarbonate. This is the first demon-
stration that a systemic acid–base disturbance is actually
present in UASFs. Serum bicarbonate level measured at 0800
hours was not statistically different between the groups when
analyzed as a single time point, thereby explaining why this
difference may not have been previously appreciated in all
published studies. However, when the sequential bicarbonate
values were compared, UASFs maintained significantly lower
serum bicarbonate level than HVs throughout most of the
day. These results further support the notion that in addition
to a renal mechanism, systemic factors such as possible
increase in acid generation contribute to the development of
acidic urine in these patients. The origin of the increased acid
load is not known yet, but can be due to increased
endogenous acid production, increased alkali loss in the
intestine, and increased absorption of exogenous organic acid
from perhaps colonic bacterial sources.
One weakness of this study was the discrepancy between
the weights of the subject in the two groups. UASFs are
typically obese and because of this characteristic, finding a
healthy matching group is in fact difficult. The HVs included
in this study were generally overweight, but not obese. It is
important to note that none of our subjects showed any
evidence of starvation ketosis during the study. In an
attempt to improve matching, we simply analyzed the five
HVs (mean±s.d.: 31.4±2.2) with highest BMI against five
subjects with lowest BMI in UASFs (mean±s.d.: 33.0±4.3,
NS); the UpH (HVs 5.86±0.20 vs. UASFs 5.29±0.13,
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Po0.05) and the fraction of net acid excreted as ammonium
(HVs 0.68±0.12 vs. UASFs 0.54±0.08, Po0.05) were both
still lower in UASFs, indicating that body weight and BMI
per se cannot account for the difference. Another drawback
is that the overnight sampling did not have the same time
resolution as the daytime sampling. We aimed to maximize
the number of study samples without causing excessive
interruption of sleep.
In conclusion, these data indicate that circadian variation
in UpH exists in both HVs and UASFs. Although UASFs
demonstrate variability in UpH, their urine remains acidic
throughout the day, leaving them unprotected from the
development of uric acid stones. The etiology of the unduly
acidic urine is due to a combination of a higher acid load to
the kidney and the underutilization of ammonia as a buffer.
One might speculate that circadian variation occurs to
protect us from persistently acidic or alkaline UpH that
predisposes to stone development. Although gastric acid
secretion contributes to variations in serum pH, it does not
appear to affect the diurnal changes in UpH. These results
provide a foundation for future studies to determine what
factors contribute to variations in UpH, whether these persist
irrespective of diet, and why UASFs maintain the circadian
variation but at a lower UpH.
MATERIALS AND METHODS
Study participants
The study was conducted at the General Clinical Research Center,
University of Texas Southwestern Medical Center (Dallas, TX) with
approval by the Institutional Review Board. All participants
provided informed consent. Study subjects included nine HVs
who had no history of kidney stones, and ten UASFs with proven
uric acid stones recruited from the Mineral Metabolism Clinic,
University of Texas Southwestern Medical Center. HVs were
recruited via Institutional Review Board-approved advertisements.
All subjects were older than 18 years of age. Excluded from both
groups were subjects with creatinine clearance o70ml/min,
proteinuria, liver disease, chronic diarrhea, peptic ulcer, or chronic
use of any medications that affect gastric acid secretion or renal
function. UASFs were instructed to hold all medications that affect
acid or base excretion for 1 week prior to initiation of the study.
Study protocol
This double-blind crossover study included two 14-day phases. In
the first phase, subjects were randomized to receive the long-acting
PPI, pantoprazole 40mg/day, or placebo. The dose was chosen based
on previous studies showing adequate suppression of gastric acid
production.42–44 The capsules were consumed each morning with
breakfast for 14 days. Participants subsequently underwent a 7-day
wash-out period, during which study medications were not
administered, and then received the alternate study medication for
14 days in the second phase. During each phase, subjects were
advised to hold blood pressure medications that might affect renal
sodium excretion.
On days 8–10 of each phase, subjects were directed to consume a
diet low in acid ash and sodium (B100mEq/day). On days 11–13 of
each phase, a frozen metabolic diet was provided by the dietary
services at the General Clinical Research Center, consisting of 30%
fat, 55% carbohydrate, 15% protein, 300mg cholesterol, 400mg
calcium, 800mg phosphorus, 100mEq sodium, 40mEq potassium,
and 3000 cm3 distilled water per day, which the subjects ingested as
outpatients. From day 13 to day 14, urine was collected for 24 h
under mineral oil and refrigerated. Subjects were then admitted
to the inpatient unit at the General Clinical Research Center after
dinner on day 13 and remained as inpatients until the morning of
day 15. During the inpatient stay, subjects were maintained on the
metabolic diet, although the volume of water was decreased to 2.7 l.
Body weight and height were obtained at the time of admission. We
monitored serum and urine ketones and detected no evidence of
ketosis throughout the study.
The diurnal study was conducted on days 14 and 15. On day 14,
an intravenous catheter was placed in the hand for collection of
free-flow blood samples. The hand was warmed in a 37-1C box for
30min prior to each blood draw to obtain arterialized samples.
Starting at 0800 hours, urine and blood were collected every 2 h
throughout the day, except for the 2 h following meals when samples
were collected hourly. To allow subjects to have reasonable sleep
overnight, samples were obtained every four hours from 2200 hours
until 0600 hours on day 15. Thus, collections were obtained at: 0800,
0900, 1000, 1200, 1300, 1400, 1600, 1800, 1900, 2000, 2200, 0200,
0600, and 0800 hours. Samples were obtained prior to ingestion
of meals, which were provided at 0800, 1200, and 1800 hours
immediately after the blood draw at those designated times.
Timed urine samples were analyzed for total volume, pH,
creatinine, electrolytes, uric acid, citrate, sulfate, ammonium,
TA, and bicarbonate. Blood sample measurements included serum
electrolytes, creatinine, uric acid, glucose, and venous pH.
Analytical procedures
A systemic multichannel analysis was performed to provide
measurements of serum creatinine, sodium, potassium, chloride,
total carbon dioxide, glucose, and uric acid (Beckman CX9ALX;
Beckman Coulter, Fullerton, CA). Venous blood gas measurements,
including serum pH and PCO2, were made using the Radiometer
ABL 5 (Radiometer America, Westlake, OH).
UpH was measured with a pH electrode and urine creatinine was
obtained via the picric acid method. Urine and fasting serum
creatinine measurements were then used to calculate endogenous
creatinine clearance. An ion-specific electrode was used to measure
urinary potassium (Beckman Coulter) and urine sulfate was
assessed by ion chromatography. Urine ammonium was measured
by the glutamate dehydrogenase method, while citrate was
assessed enzymatically with reagents from Boehringer-Mannheim
Biochemicals (Indianapolis, IN). Urinary bicarbonate was calculated
from measurements of UpH and PCO2, while titratable acid was
assessed by the automated burette titration system (Radiometer,
Copenhagen, Denmark). Uric acid was determined via the uricase
method using alkalinized samples to prevent precipitation. NAE was
calculated using the sum of ammonium and TA minus the sum
of citrate and bicarbonate in mEq. The urinary anion gap was
calculated as the sum of all anions (chloride, sulfate, phosphate,
urate, creatinate, oxalate, citrate, bicarbonate) subtracted from the
sum of all cations (sodium, potassium, calcium, magnesium,
ammonium), all in milliequivalents.
Statistical analyses
Data are presented as mean±standard deviation (s.d.). Demo-
graphic variables were compared between UASFs and HVs using
the two-sample t-tests. Twenty-four-hour urine results and serum
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biochemical data were compared using mixed-model repeated-
measures analysis followed by least-square means contrasts to
compare the two groups or to compare the two treatment phases.
Mixed-model repeated-measures analysis was also used for the
diurnal studies. The models consisted of group, phase, and time
main effects and interactions, with subject modeled as a random
effect. An autoregressive covariance structure was used to model the
repeated time effect and account for the correlation within
individuals.45 The interaction terms from these models were used
to test for differences in diurnal pattern. The difference in diurnal
pattern between the UASF and HV groups was assessed using the
group-by-time interaction factor. The difference in diurnal pattern
between the placebo and PPI phases was assessed using the phase-
by-time interaction factor. A significant interaction (Po0.05)
indicates that the groups do not have the same pattern over time.
Urine bicarbonate was rank-transformed prior to analysis. Statistical
analyses were performed with SAS version 9.2 (SAS Institute,
Cary, NC).
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